Don't Miss: 2 Top Healthcare Stocks Poised for Major Upside

CVS Health is implementing strategic adjustments expected to enhance its business performance this year. Meanwhile, Vertex Pharmaceuticals is projected to achieve substantial commercial and clinical progress by 2026.

For CVS Health, our proprietary data shows an RS Score of 74.37, placing it in the 70.13th percentile within its country and the 72.77th percentile in its sector. Valuation stands out as a strong area for CVS, scoring 96.70. However, the company exhibits weaker scores in Growth (79.96), Profitability (76.21), Momentum (43.34), and EPS Revisions (72.00). Want to discover which stocks rank the highest? Start your free 7-day trial at rankedstocks.com.